Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

MDS 2023 | Phase II study of risvodetinib in Parkinson’s disease

Milton Werner, PhD, Inhibikase Therapeutics, Inc., Atlanta, GA, discusses the development of risvodetinib, a selective c-Abl kinase inhibitor. Research studies show that administering this inhibitor to animal models of Parkinson’s disease completely reverses the disease progression, even in advanced stages. Notably, their studies also examine the role of the gastrointestinal (GI) tract in Parkinson’s disease, as patients often experience severe GI issues related to the same neural neuron class found in their brains. This unique approach involves analyzing both brain and GI tract outcomes in a systemic manner. The ongoing Phase II trial has already produced promising results, and further studies are underway to confirm the therapeutic potential of risvodetinib. This interview took place at the 2023 International Congress of Parkinson’s Disease and Movement Disorders in Copenhagen, Denmark.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.


Milton Werner reports the following disclosures:
Founder and largest shareholder, Inhibikase Therapeutics, Inc.